

CORRECTION

Open Access

Correction: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus

Juliana Levy*, Roberta A Cobas, Marília B Gomes

Correction

Since publication of our article [1], we have noticed that amendments to the second sentence of the “Study Design” section are required as this should read as follows:

“Approved by the local ethics committee, patient enrolment was restricted to the following patients: those aged 18 years and greater and taking immediate release metformin alone or in combination with other oral agents, those excluded had symptoms of poor diabetes control, were pregnant, had serum creatinine levels >1.3 mg/dL (female) or 1.4 mg/dL (male), nephropathy, evidence of hepatic disease or history of alcohol abuse.”

We apologize for any inconvenience or confusion that this may have caused.

Received: 24 August 2010 Accepted: 25 August 2010
Published: 25 August 2010

Reference

1. Levy J, Cobas RA, Gomes MB: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. *Diabetol Metab Syndr* 2010, **2**:16.

doi:10.1186/1758-5996-2-57

Cite this article as: Levy et al.: Correction: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. *Diabetology & Metabolic Syndrome* 2010 **2**:57.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



* Correspondence: julevy@ig.com.br
Department of Medicine, Diabetes Unit, State University of Rio de Janeiro, Rio de Janeiro, Brazil